Intralesional therapy for metastatic melanoma

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 18, 2014, Pages 2629-2639

  Sloot, Sarah ^a   Rashid, Omar M ^b   Zager, Jonathan S ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

In transit melanoma; Intralesional; Locoregional recurrence; Melanoma

Indexed keywords

BCG VACCINE; DIPHENCYPRONE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERLEUKIN 2; ROSE BENGAL; TALIMOGENE LAHERPAREPVEC; TOPICAL AGENT; VELIMOGENE ALIPLASMID; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

BYSTANDER EFFECT; CELLULAR IMMUNITY; ELECTROCHEMOTHERAPY; HUMAN; IMMUNE RESPONSE; INTRALESIONAL DRUG ADMINISTRATION; METASTATIC MELANOMA; MYCOBACTERIUM BOVIS BCG; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TOPICAL TREATMENT; TREATMENT RESPONSE; TUMOR VOLUME; CLINICAL TRIAL (TOPIC); MELANOMA; SKIN NEOPLASMS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; ELECTROCHEMOTHERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRALESIONAL; MELANOMA; SKIN NEOPLASMS;

EID: 84910641797     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.967682     Document Type: Review

References (98)

1. Temple-Oberle CF, Byers BA, Hurdle V, et al. Intra-lesional interleukin-2 therapy for in transit melanoma. J Surg Oncol 2014;109: 327-31
2. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19: 3635-48
3. Coit DG, Andtbacka R, Anker CJ, et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11: 395-407
4. Sanki A, Kam PC, Thompson JF. Long-Term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 2007;245: 591-6
5. Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. Ann Surg Oncol 2012;19: 1637-43
6. Testori A, Faries MB, Thompson JF, et al. Local and intralesional therapy of in-Transit melanoma metastases. J Surg Oncol 2011;104: 391-6
7. Coley WB. The treatment of malignant tumors by repeated innoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893;10: 487-511
8. Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet 1907;i: 927-33; 96-1003
9. Sarnaik AA, Zager JS, Sondak VK. Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep 2007;9: 417-27
10. Abbott AM, Zager JS. Locoregional therapies in melanoma. Surg Clin North Am 2014;94(5): 1003-15
11. Andtbacka RH, Ross MI, Delman K, et al. Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T-VEC) in the OPTiM Study and the Contribution of Surgery to Response [abstract 52]. SSO; 12-15 March 2014; Phoenix, Arizona
12. Andtbacka RHI, Collichio FA, Amatruda T, et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocytemacrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 2013;31(Suppl): abstract LBA9008
13. Sarnaik AA, Crago G, Liu H, et al. Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions. J Clin Oncol 2014;32(5s Suppl): abstract 9028
14. Agarwala SS, Thompson JF, Smithers BM, et al. Chemoablation of metastatic melanoma with rose bengal (PV-10). J Clin Oncol 2010;28(15-suppl): abstract 8534
15. Hersey P, Gallagher S. Intralesional immunotherapy for melanoma. J Surg Oncol 2014;109: 320-6
16. Bedikian AY, Richards J, Kharkevitch D, et al. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010;20: 218-26
17. Green DS, Bodman-Smith MD, Dalgleish AG, et al. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007;156: 337-45
18. Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 2010;116: 4139-46
19. Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Expert Opin Biol Ther 2008;8: 839-44
20. Plautz GE, Yang ZY, Wu BY, et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993;90: 4645-9
21. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93: 15388-93
22. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993;90: 11307-11
23. Stopeck AT, Hersh EM, Akporiaye ET, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997;15: 341-9
24. Stopeck AT, Jones A, Hersh EM, et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001;7: 2285-91
25. Gonzalez R, Hutchins L, Nemunaitis J, et al. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006;16: 521-6
26. Richards J, Thompson J, Atkins MB, et al. A controlled, randomized Phase III trial comparing the response to dacarbazine with and without Allovectin-7 in patients with metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 2002;21: 346a
27. Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet 1979;149: 17-21
28. Seigler HF, Shingleton WW, Pickrell KL. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-Treated tumor cells to manage melanoma; A clinical assessment. Plast Reconstr Surg 1975;55: 294-8
29. Cohen MH, Elin RJ, Cohen BJ. Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guerin therapy for locally metastatic melanoma. Cancer Immunol Immunother 1991;32: 315-24
30. Robinson JC. Risks of BCG intralesional therapy: an experience with melanoma. J Surg Oncol 1977;9: 587-93
31. Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998;77: 2336-42
32. Mali B, Jarm T, Snoj M, et al. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-Analysis. Eur J Surg Oncol 2013;39: 4-16
33. Heller R, Jaroszeski MJ, Reintgen DS, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998;83: 148-57
34. Byrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005;15: 45-51
35. Rodriguez-Cuevas S, Barroso-Bravo S, Almanza-Estrada J, et al. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res 2001;32: 273-6
36. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010;17: 718-30
37. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999;6: 409-22
38. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996;6: 247-55
39. Ridolfi L, Ridolfi R, Ascari-Raccagni A, et al. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol 2001;15: 218-23
40. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colonystimulating factor-encoding, secondgeneration oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27: 5763-71
41. Choi KJ, Kim JH, Lee YS, et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 2006;13: 1010-20
42. Eklund JW, Kuzel TM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004;16: 542-6
43. Adler A, Stein JA, Kedar E, et al. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study. J Biol Response Mod 1984;3: 491-500
44. Dummer R, Rochlitz C, Velu T, et al. Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 2008;16: 985-94
45. Garcia MS, Ono Y, Martinez SR, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Res 2011;21: 235-43
46. Green DS, Dalgleish AG, Belonwu N, et al. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 2008;159: 606-14
47. Tartour E, Mehtali M, Sastre-Garau X, et al. Phase I clinical trial with IL-2-Transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. Br J Cancer 2000;83: 1454-61
48. Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, et al. [Experience in the treatment of cutaneous in-Transit melanoma metastases and satellitosis with intralesional interleukin-2]. Actas Dermosifiliogr 2009;100: 571-85
49. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-Tissue melanoma metastases. Br J Cancer 2003;89: 1620-6
50. Boyd KU, Wehrli BM, Temple CL. Intra-lesional interleukin-2 for the treatment of in-Transit melanoma. J Surg Oncol 2011;104: 711-17
51. Tan CY, Neuhaus SJ. Novel use of Rose Bengal (PV-10) in two cases of refractory scalp sarcoma. ANZ J Surg 2013;83: 93
52. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008;18: 405-11
53. Delprat GD Jr. Studies on liver function: rose bengal elimination from the blood as influenced by liver injury. Arch Intern Med 1923;32: 401-10
54. Foote MC, Burmeister BH, Thomas J, et al. A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res 2010;20: 48-51
55. Toomey P, Kodumudi K, Weber A, et al. Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS One 2013;8: e68561
56. Agarwala SS, Thompson JF, Smithers BM, et al. Immuno-chemoablation of metastatic melanoma with intralesional Rose Bengal [abstract]. Ann Oncol 2012;23: Suppl 9
57. Agarwala S, Thompson JF, Smithers BM, et al. Locoregional disease control in metastatic melanoma: exploratory analysis from phase 2 testing of intralesional rose bengal [abstract]. Eur J Cancer 2013;49: 873-4
58. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-Tumour properties. Gene Ther 2003;10: 292-303
59. Andtbacka RH, Kaufman H, Daniels GA, et al. CALM study: a phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma. J Clin Oncol 2013;31: abstract TPS3128
60. Kaufman HL, Andtbacka RH, Collichio FA, et al. Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocytemacrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma [abstract]. ASCO 2014;32: Suppl 5; abstract 9008a
61. Puzanov I, Milhem MM, Andtbacka RHI, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol 2014;32(5s Suppl): abstract 9029
62. Erickson C, Miller SJ. Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery. Int J Dermatol 2010;49: 482-91
63. Shistik G, Prakash AV, Fenske NA, et al. Treatment of locally metastatic melanoma: a novel approach. J Drugs Dermatol 2007;6: 830-2
64. Florin V, Desmedt E, Vercambre-Darras S, Mortier L. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Invest New Drugs 2012;30: 1641-5
65. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004;29: 15-21
66. Quigley EA, Halpern AC. Microinvasive melanoma: cutaneous pharmacotherapeutic approaches. Am J Clin Dermatol 2013;14: 125-37
67. Junkins-Hopkins JM. Imiquimod use in the treatment of lentigo maligna. J Am Acad Dermatol 2009;61: 865-7
68. Kidner TB, Morton DL, Lee DJ, et al. Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-Transit melanoma. J Immunother 2012;35: 716-20
69. Buckley DA, Du Vivier AW. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol 2001;145: 385-405
70. van der Steen PH, Happle R. Topical immunotherapy of alopecia areata. Dermatol Clin 1993;11: 619-22
71. Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J Am Acad Dermatol 2007;56: 869-71
72. Damian DL, Saw RP, Thompson JF. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol 2014;109: 308-13
73. Damian DL, Shannon KF, Saw RP, et al. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol 2009;50: 266-71
74. Damian DL, Thompson JF. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg. Am J Clin Dermatol 2011;12: 403-4
75. Hinz T, Ehler LK, Bieber T, et al. Complete remission of extensive cutaneous metastatic melanoma on the scalp under topical monoimmunotherapy with diphenylcyclopropenone. Eur J Dermatol 2013;23: 532-3
76. Kim YJ. Topical diphencyprone as an effective treatment for cutaneous metastatic melanoma. Ann Dermatol 2012;24: 373-5
77. Sowden J, Paramsothy Y, Smith AG. Malignant melanoma arising in the scar of lupus vulgaris and response to treatment with topical azelaic acid. Clin Exp Dermatol 1988;13: 353-6
78. Nazzaro-Porro M, Passi S, Zina G, et al. Effect of azelaic acid on human malignant melanoma. Lancet 1980;1: 1109-11
79. Nazzaro-Porro M, Breathnach AS, Balus L, et al. A case of recurrent (following surgery x2) invasive malignant melanoma with satellitosis (stage IIIA) successfully resolving after azelaic acid treatment administered by several routes. Clin Exp Dermatol 1996;21: 321-3
80. Schallreuter KU, Wood JM, Mensing H, Breitbart EW. Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine. Cancer Chemother Pharmacol 1991;29: 167-71
81. Oratz R, Hauschild A, Sebastian G, et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res 2003;13: 59-66
82. Kaufman HL, Deraffele G, Mitcham J, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005;115: 1903-12
83. Triozzi PL, Allen KO, Carlisle RR, et al. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 2005;11: 4168-75
84. Hofmann MA, Kors C, Audring H, et al. Phase 1 evaluation of intralesionally injected TLR9-Agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008;31: 520-7
85. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 2003;63: 8466-75
86. Guo J, Zhu J, Sheng X, et al. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer 2007;120: 2418-25
87. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986;83: 8694-8
88. Truchetet F, Heid E, Friedel J, et al. D. N.C.B. for malignant melanoma: significance in the treatment strategy. Anticancer Res 1989;9: 1531-6
89. Illig L, Paul E, Bodeker RH. Epifocal dinitrochlorobenzene therapy in malignant melanoma (experience during the last eight years). Anticancer Res 1984;4: 293-8
90. Terheyden P, Kortum AK, Schulze HJ, et al. Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. J Cancer Res Clin Oncol 2007;133: 437-44
91. Ryan RF, Krementz ET, Litwin MS. A role for topical 5-fluorouracil therapy in melanoma. J Surg Oncol 1988;38: 250-6
92. Rapprich H, Hagedorn M. Intralesional therapy of metastatic spreading melanoma with beta-interferon. J Dtsch Dermatol Ges 2006;4: 743-6
93. Ikic D, Spaventi S, Padovan I, et al. Local interferon therapy for melanoma patients. Int J Dermatol 1995;34: 872-4
94. Ikic D, Nola P, Maricic Z, et al. Application of human leucocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma. Lancet 1981;1: 1022-4
95. von Moos R, Schaffner R, Cathomas R, et al. Intratumoral therapy with interferon-Alpha in a locoregional advanced malignant blue nevus: a brief communication. J Immunother 2010;33: 92-5
96. von Wussow P, Block B, Hartmann F, et al. Intralesional interferon-Alpha therapy in advanced malignant melanoma. Cancer 1988;61: 1071-4
97. Kirkwood JM, Ernstoff MS. Role of interferons in the therapy of melanoma. J Invest Dermatol 1990;95: 180S-4S
98. Karakousis CP, Douglass HO Jr, Yeracaris PM, et al. BCG immunotherapy in patients with malignant melanoma. Arch Surg 1976;111: 716-18